Jason P Rhodes sold $16M of DYN
director at Dyne Therapeutics, Inc.. 834,302 shares at an average of $19.75, traded Apr 20, 2026, filed Apr 22, 2026.
Score components
- +15RoleDirector
- +25Trade size$16.5M at market
- +10Share of holdings soldSold 43% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.7%, 3m +18.0%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001577014-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -71,676 | $20.06 | $1.4M | 1,886,751 | Apr 22, 2026 |
| Apr 20, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -142,604 | $20.06 | $2.9M | 5,554,904 | Apr 22, 2026 |
| Apr 20, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,401 | $20.06 | $28k | 14,561 | Apr 22, 2026 |
| Apr 20, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -56,368 | $20.06 | $1.1M | 1,402,200 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -71,499 | $19.51 | $1.4M | 1,815,252 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -142,253 | $19.51 | $2.8M | 5,412,651 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,398 | $19.51 | $27k | 13,163 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -56,228 | $19.51 | $1.1M | 1,345,972 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -769 | $20.05 | $15k | 1,814,483 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,530 | $20.05 | $31k | 5,411,121 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -15 | $20.05 | $301 | 13,148 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -605 | $20.05 | $12k | 1,345,367 | Apr 22, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -75,866 | $19.68 | $1.5M | 1,738,617 | Apr 22, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -150,942 | $19.68 | $3.0M | 5,260,179 | Apr 22, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,485 | $19.68 | $29k | 11,663 | Apr 22, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -59,663 | $19.68 | $1.2M | 1,285,704 | Apr 22, 2026 |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $40k 2,500 shares | +10% | |
| 30Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $107k 5,658 shares | -2% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 31Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $131k 4,986 shares | -1% | |
| 55Moderate | Dyne Therapeutics, Inc. | Jason P Rhodes director | $65M 2,586,928 shares | -64% | |
| 23Weak | Dyne Therapeutics, Inc. | Erick Lucera Chief Financial Officer | $47k 1,797 shares | -1% | |
| 16Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $41k 1,556 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $5,939 226 shares | -0% | |
| 20Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $6.7M 261,460 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.